Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | IL6 |
Clinical data | |
Trade names | Artlegia |
Routes of administration | Subcutaneous |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 31 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Molar mass | 146000 Da |
(what is this?) (verify) |
Olokizumab (OKZ) sold under the name Artlegia, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and COVID-19. It is a humanized monoclonal antibody against the interleukin-6 (IL-6). IL-6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases. Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor.[1] Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex.[2] Olokizumab was developed by R-Pharm group, and was launched in 2020.[3]
pmid36792848
was invoked but never defined (see the help page).